Manzatin Diaper Rash Skin Protectant Ointment
NDC Package 55715-005-01
Package Information
Manzatin Diaper Rash Skin Protectant (zinc oxide) ointment is a medication used to treat and prevent diaper rash and other minor skin irritations (e.g., burns, cuts, scrapes). This formulation utilizes a ointment delivery system. Marketed by Laboratorios Zepol S.a., this product is identified by NDC 55715-005 and is authorized under FDA application M016.
Identification & Billing
- RxCUI: 1039181 - zinc oxide 18 % Topical Ointment
- RxCUI: 1039181 - zinc oxide 0.18 MG/MG Topical Ointment
- RxCUI: 1039181 - ZNO 0.18 MG/MG Topical Ointment
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55715 - Laboratorios Zepol S.a.
- 55715-005 - Manzatin Diaper Rash Skin Protectant
- 55715-005-01 - 90 g in 1 TUBE
- 55715-005 - Manzatin Diaper Rash Skin Protectant
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (55715-005). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55715-005-01 identifies a specific commercial package of 90 g in 1 tube of Manzatin Diaper Rash Skin Protectant, a human over the counter drug labeled by Laboratorios Zepol S.a.. This ointment is formulated for topical use and contains zinc oxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Laboratorios Zepol S.a. on November 01, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat and prevent diaper rash and other minor skin irritations (e.g., burns, cuts, scrapes). It works by forming a barrier on the skin to protect it from irritants/moisture.
How is this Laboratorios Zepol S.a. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55715000501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.